Predictive Oncology Stock Performance
| POAI Stock | USD 0.85 0.02 2.41% |
The company holds a Beta of -0.0099, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Predictive Oncology are expected to decrease at a much lower rate. During the bear market, Predictive Oncology is likely to outperform the market. At this point, Predictive Oncology has a negative expected return of -0.14%. Please make sure to check Predictive Oncology's total risk alpha and the relationship between the skewness and period momentum indicator , to decide if Predictive Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Predictive Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders. ...more
| Begin Period Cash Flow | 8.7 M |
Predictive | Build AI portfolio with Predictive Stock |
Predictive Oncology Relative Risk vs. Return Landscape
If you would invest 98.00 in Predictive Oncology on April 8, 2025 and sell it today you would lose (13.00) from holding Predictive Oncology or give up 13.27% of portfolio value over 90 days. Predictive Oncology is currently does not generate positive expected returns and assumes 4.2879% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Predictive, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Predictive Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Predictive Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Predictive Oncology, and traders can use it to determine the average amount a Predictive Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0327
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | POAI |
Estimated Market Risk
| 4.29 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Predictive Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Predictive Oncology by adding Predictive Oncology to a well-diversified portfolio.
Predictive Oncology Fundamentals Growth
Predictive Stock prices reflect investors' perceptions of the future prospects and financial health of Predictive Oncology, and Predictive Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Predictive Stock performance.
| Return On Equity | -4.9 | ||||
| Return On Asset | -0.73 | ||||
| Operating Margin | (20.73) % | ||||
| Current Valuation | 6.42 M | ||||
| Shares Outstanding | 8.93 M | ||||
| Price To Book | 1.43 X | ||||
| Price To Sales | 4.39 X | ||||
| Revenue | 1.62 M | ||||
| EBITDA | (10.16 M) | ||||
| Cash And Equivalents | 25.39 M | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 2.13 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (10.97 M) | ||||
| Earnings Per Share | (1.43) X | ||||
| Total Asset | 4.97 M | ||||
| Retained Earnings | (180.43 M) | ||||
About Predictive Oncology Performance
By evaluating Predictive Oncology's fundamental ratios, stakeholders can gain valuable insights into Predictive Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Predictive Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Predictive Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. Predictive Oncology operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.Things to note about Predictive Oncology performance evaluation
Checking the ongoing alerts about Predictive Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Predictive Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Predictive Oncology generated a negative expected return over the last 90 days | |
| Predictive Oncology has some characteristics of a very speculative penny stock | |
| Predictive Oncology has high historical volatility and very poor performance | |
| Predictive Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.62 M. Net Loss for the year was (10.86 M) with profit before overhead, payroll, taxes, and interest of 880.45 K. | |
| Predictive Oncology currently holds about 25.39 M in cash with (10.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. |
- Analyzing Predictive Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Predictive Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Predictive Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Predictive Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Predictive Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Predictive Oncology's stock. These opinions can provide insight into Predictive Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |